Brief Report

Cost of deep brain stimulation for the treatment of Parkinson’s disease by surgical stimulation sites

By Kevin T. Stroupe PhD*, Frances M. Weaver PhD, Lishan Cao MS, Dolores Ippolito MPH, Brandon R. Barton MD, MS, Inger E. Burnett-Zeigler PhD, Robert G. Holloway MD, MPH, Barbara G. Vickrey MD, MPH, Tanya Simuni MD and Kenneth A. Follett MD, PhD

Objective: To assess costs and effectiveness of deep brain stimulation (DBS) of the internal globus pallidum (GPi) versus subthalamic nucleus (STN) from the provider and societal perspectives for Parkinson’s disease (PD) patients in a multicenter randomized trial.

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease

By Stewart A. Factor DO*, Kenneth Wolski MD, Daniel M. Togasaki MD, PhD, Susan Huyck DrPH, Marc Cantillon MD†, T.W. Ho MD‡, Robert A. Hauser MD, MBA and Emmanuelle Pourcher MD

Preladenant is a selective adenosine A2A receptor antagonist under investigation for Parkinson’s disease treatment.

Adenosine A_2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease

By Yoshikuni Mizuno MD*, Tomoyoshi Kondo MD and the Japanese Istradefylline Study Group

We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson’s disease patients with motor complications in Japan.

Brief Report

Footer